Presentation of preclinical study highlighting anti-cancer activity of rencofilstat in combination with proteosome inhibitors

Edison, n.j., jan. 10, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases, announced that its research collaborator, carlos perez-stable, phd, from the university of miami miller school of medicine and miami veterans affairs/research, today presented new findings from a preclinical study on the company's lead drug candidate, rencofilstat, a potent inhibitor of cyclophilins, in a presentation at the 2023 state of florida cancer symposium in tampa, florida.
HEPA Ratings Summary
HEPA Quant Ranking